Evidence map›Paper›PMID 24457946›Full record

ArticleJournal of clinical gastroenterology2015

Distinct features in natural history and outcomes of acute hepatitis C.

Chalermrat Bunchorntavakul, Lisa M Jones, Masahiro Kikuchi, Mary E Valiga, David E Kaplan, Frederick A Nunes, Ayse Aytaman, K Rajender Reddy, Kyong-Mi Chang

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pharmacological interventions for acute hepatitis C infection.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Pooled it
  3. Article
  4. Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Chalermrat Bunchorntavakul*Department of Medicine, University of Pennsylvania ‡Department of Medicine, Division of Gastroenterology and Hepatology, Philadelphia VA Medical Center §Pennsylvania Hospital, Philadelphia, PA †Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand ∥VA New York Harbor Healthcare System, Brooklyn, NY.
Lisa M Jones
Masahiro Kikuchi
Mary E Valiga
David E Kaplan
Frederick A Nunes
Ayse Aytaman
K Rajender Reddy
Kyong-Mi Chang
University of Pennsylvania · USPhiladelphia VA Medical Center · USPennsylvania Hospital · USVA NY Harbor Healthcare System · US

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
UNIVERSITY OF PENNSYLVANIA TRAINING IN GASTROENTEROLOGYT32DK007066 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI JONATHAN P KATZ · 1986 to 2026
$11.7M
Mentored Career Development in Patient Oriented ResearchK12RR017625 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI RADER, DANIEL JAMES · 2002 to 2006
$4.1M
CELLULAR IMMUNITY--OUTCOME HEPATITIS C VIRUS INFECTIONR01AI047519 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 1999 to 2010
$3.1M
ALCOHOL/CELLULAR IMMUNITY IN HCV AND HIV INFECTIONR01AA012849 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 2000 to 2004
$1.9M
NCRR NIH HHS K12 RR017625NCRR NIH HHS K12-RR-017625NCRR NIH HHS M01 RR000040NCRR NIH HHS M01-RR00040NIAAA NIH HHS R01 AA012849NIAAA NIH HHS R01-AA-12849NIAID NIH HHS R01 AI047519NIAID NIH HHS R01-AI-47519NIDDK NIH HHS P30 DK050306NIDDK NIH HHS P30DK50306NIDDK NIH HHS T32 DK007066
6 · The paper itself

Abstract

backgroundAcute hepatitis C (AHCV) provides a diagnostic challenge with diverse clinical presentations. GOALS: This study was aimed to examine the clinical and demographic features as well as outcomes in AHCV patients identified from inpatient and outpatient hospital settings. STUDY: Patients with suspected AHCV were recruited from Philadelphia VA Medical Center, Hospital of University of Pennsylvania and Brooklyn VA Medical Center between 2000 and 2010. AHCV was diagnosed by acute serum alanine aminotransferase elevation with anti-hepatitis C virus (HCV) seroconversion, HCV-RNA fluctuations above 1 log, and/or recent high-risk exposure without prior HCV infection, excluding those with human immunodeficiency virus infection. Clinical and therapeutic outcomes were monitored for at least 6 months.

resultsA total of 40 AHCV patients were enrolled with a median follow-up of 129 weeks. They were mostly men (68%) and whites (73%) with median age of 43 years, diverse risk factors (33% injection drugs, 20% health care-associated, 3% sexual, and 45% unknown), and wide variations in peak alanine aminotransferase (143 to 3435 U/L) and total bilirubin levels (0.4 to 19.3 mg/dL). Viremia resolved spontaneously in 23% and persisted without therapy in 27%, whereas 50% received interferon α-based therapy with 90% cure (18/20). Distinct clinical scenarios included: (1) wide viremic fluctuations >1 log (65%) and intermittent HCV-RNA negativity; (2) autoantibodies (25% antinuclear antibodies, 69% antismooth muscle antibodies) or autoimmune features; (3) delayed spontaneous viral clearance in 2 patients; (4) rapid cirrhosis progression in 2 patients.

conclusionsAHCV is a heterogenous disease that requires careful monitoring. The lack of apparent risk factor in high proportion of patients and its diverse presentations warrant diagnostic vigilance.

Indexed as

AdultAlanine TransaminaseAntiviral AgentsBilirubinFemaleHepacivirusHepatitis CHepatitis C AntibodiesHumansInterferon-alphaMaleMiddle AgedRisk FactorsRNA, ViralTreatment OutcomeViremiaAlanine TransaminaseAntiviral AgentsBilirubinHepatitis C AntibodiesInterferon-alphaRNA, Viral

Identifiers

PMID24457946
PMCPMC4112167
OpenAlexW1981097640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.